TABLE 1.

Summary of Indications, Radiophysical Data, and Administered Activity

Agent	Indication	Emission(s)	Physical half-life	Administered activity
⁸⁹Sr-chloride	Relief of bone pain caused by osseous metastases	β, rare γ	50.5 days	148 MBq (4.0 mCi) is recommended; alternative weight-based activity of 1.5-2.2 MBq/kg (40-60 μCi/kg) may be used
¹⁵³Sm-lexidronam	Pain relief in patients with osteoblastic metastases seen on radionuclide bone scan	β, γ	1.9 days	Weight-based activity of 37 MBq (1.0 mCi) per kg
²²³Ra-dichloride	Treatment of patients with castration-resistant prostate cancer with symptomatic osseous metastases and no known visceral metastatic disease	Predominantly α, with additional β and γ	11.4 days	Weight-based activity of 55 kBq (1.49 µCi) per kg